<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Signal transducer and activator of transcription 3 (STAT3) plays a critical role in cell survival and proliferation </plain></SENT>
<SENT sid="1" pm="."><plain>Constitutive activation of STAT3 is strongly correlated with pathogenesis of various types of <z:mp ids='MP_0002018'>malignant tumors</z:mp> including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), and therefore is a major focus in the development of anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> agents </plain></SENT>
<SENT sid="2" pm="."><plain>Pien Tze Huang (PZH), a well-known traditional Chinese formula prescribed already in the Ming Dynasty, has been demonstrated to be clinically effective in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the precise mechanism of its anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> activity remains largely unknown </plain></SENT>
<SENT sid="4" pm="."><plain>In the present study we evaluated the efficacy of PZH against <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in vivo in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> mouse <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, and investigated the underlying molecular mechanisms </plain></SENT>
<SENT sid="5" pm="."><plain>We found that administration of PZH reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> weight but had no effect on body <z:mp ids='MP_0005456'>weight gain</z:mp> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> mice, demonstrating that PZH can inhibit <z:hpo ids='HP_0003003'>colon cancer</z:hpo> growth in vivo without apparent adverse effect </plain></SENT>
<SENT sid="6" pm="."><plain>We also observed that PZH treatment inhibited the phosphorylation level of STAT3 in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues </plain></SENT>
<SENT sid="7" pm="."><plain>Consequently, the inhibitory effect of PZH on STAT3 activation resulted in the up-regulation of Bax/Bcl-2 ratio as well as down-regulation of Cyclin D1 and CDK4 expression, leading to the induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> as well as the inhibition of cell proliferation </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that promotion of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and inhibition of proliferation via suppression of STAT3 pathway might be one of the mechanisms by which PZH treats <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>